Ardelyx Inc (ARDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $776.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Ardelyx Inc (ARDX) Stock Forecast
Analysts expect Ardelyx (ARDX) to earn -$0.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $482.24M. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 9.1% |
| Buy | 10 | 90.9% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 26.1%.
- Fiscal year ending Dec 31, 2026
- -$0.20
- EPS consensus, revenue $482.24M
- Fiscal year ending Dec 31, 2027
- $0.16
- EPS consensus, revenue $608.01M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.23 to -$0.18 | 7 | $482.24M | $472.88M to $491.56M | 11 |
| Dec 31, 2027 | $0.16 | $0.04 to $0.49 | 7 | $608.01M | $550.50M to $678.53M | 11 |
Quarterly Estimates
The EPS consensus falls from $0.04 for the quarter ending Dec 31, 2026 to -$0.05 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.04 | $0.02 to $0.06 | 13 | $142.01M | $127.28M to $155.98M | 13 |
| Mar 31, 2027 | -$0.05 | -$0.08 to -$0.02 | 4 | $115.82M | $101.60M to $122.17M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.07.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.20 | -$0.19 | -$0.19 | -$0.20 | -$0.07 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.16 | $0.29 | $0.29 | $0.25 | $0.49 | -67.9% |
| Quarter ending Mar 31, 2027 | -$0.05 | -$0.04 | -$0.04 | -$0.03 | -$0.02 | N/A |
Frequently Asked Questions About ARDX
What is the ARDX stock forecast?
Consensus analyst estimates put Ardelyx's EPS at -$0.20 for the fiscal year ending Dec 31, 2026, on revenue of $482.24M. The consensus rating from 11 analysts is Buy.
How do analysts rate ARDX stock?
Of 11 analysts covering Ardelyx, 1 rates it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ARDX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.20, with estimates from -$0.23 to -$0.18 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.16, with estimates from $0.04 to $0.49 from 7 analysts.
What revenue do analysts expect from Ardelyx next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $482.24M, with estimates from $472.88M to $491.56M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $608.01M, with estimates from $550.50M to $678.53M.
How many analysts cover ARDX?
11 analysts rate Ardelyx stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ARDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts